<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36899952</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>06</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>Pathogenesis Underlying Neurological Manifestations of Long COVID Syndrome and Potential Therapeutics.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">816</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells12050816</ELocationID><Abstract><AbstractText>The development of long-term symptoms of coronavirus disease 2019 (COVID-19) more than four weeks after primary infection, termed "long COVID" or post-acute sequela of COVID-19 (PASC), can implicate persistent neurological complications in up to one third of patients and present as fatigue, "brain fog", headaches, cognitive impairment, dysautonomia, neuropsychiatric symptoms, anosmia, hypogeusia, and peripheral neuropathy. Pathogenic mechanisms of these symptoms of long COVID remain largely unclear; however, several hypotheses implicate both nervous system and systemic pathogenic mechanisms such as SARS-CoV2 viral persistence and neuroinvasion, abnormal immunological response, autoimmunity, coagulopathies, and endotheliopathy. Outside of the CNS, SARS-CoV-2 can invade the support and stem cells of the olfactory epithelium leading to persistent alterations to olfactory function. SARS-CoV-2 infection may induce abnormalities in innate and adaptive immunity including monocyte expansion, T-cell exhaustion, and prolonged cytokine release, which may cause neuroinflammatory responses and microglia activation, white matter abnormalities, and microvascular changes. Additionally, microvascular clot formation can occlude capillaries and endotheliopathy, due to SARS-CoV-2 protease activity and complement activation, can contribute to hypoxic neuronal injury and blood-brain barrier dysfunction, respectively. Current therapeutics target pathological mechanisms by employing antivirals, decreasing inflammation, and promoting olfactory epithelium regeneration. Thus, from laboratory evidence and clinical trials in the literature, we sought to synthesize the pathophysiological pathways underlying neurological symptoms of long COVID and potential therapeutics.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Leng</LastName><ForeName>Albert</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8049-7624</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Manuj</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7374-2246</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmad</LastName><ForeName>Syed Ameen</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Premraj</LastName><ForeName>Lavienraj</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-3682-3722</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Griffith University School of Medicine, Gold Coast, Brisbane, QLD 4215, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Critical Care Research Group, The Prince Charles Hospital, Brisbane, QLD 4032, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wildi</LastName><ForeName>Karin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-6520-2696</Identifier><AffiliationInfo><Affiliation>Critical Care Research Group, The Prince Charles Hospital, Brisbane, QLD 4032, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li Bassi</LastName><ForeName>Gianluigi</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Critical Care Research Group, The Prince Charles Hospital, Brisbane, QLD 4032, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, University of Queensland, Brisbane, QLD 4072, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD 4000, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Intensive Care Unit, St Andrew's War Memorial Hospital and the Wesley Hospital, Uniting Care Hospitals, Brisbane, QLD 4000, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wesley Medical Research, Auchenflower, QLD 4066, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pardo</LastName><ForeName>Carlos A</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0000-0002-4128-5335</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Alex</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Neurosciences Critical Care, Department of Neurosurgery, UT Houston, Houston, TX 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cho</LastName><ForeName>Sung-Min</ForeName><Initials>SM</Initials><Identifier Source="ORCID">0000-0002-5132-0958</Identifier><AffiliationInfo><Affiliation>Divisions of Neurosciences Critical Care and Cardiac Surgery, Departments of Neurology, Surgery, Anesthesiology and Critical Care Medicine and Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 HL157610</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>L30 HL165486</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009422" MajorTopicYN="Y">Nervous System Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">brain fog</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">neurological complication</Keyword><Keyword MajorTopicYN="N">neurological manifestations</Keyword><Keyword MajorTopicYN="N">outcome</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>11</Day><Hour>1</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36899952</ArticleId><ArticleId IdType="pmc">PMC10001044</ArticleId><ArticleId IdType="doi">10.3390/cells12050816</ArticleId><ArticleId IdType="pii">cells12050816</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sudre C.H., Murray B., Varsavsky T. Attributes and predictors of long COVID [published correction appears in Nat Med] Nat. Med. 2021;27:626&#x2013;631. doi: 10.1038/s41591-021-01292-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D., Sun A., Ssentongo A.E. Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection: A Systematic Review. JAMA Netw. Open. 2021;4:e2128568. doi: 10.1001/jamanetworkopen.2021.28568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.28568</ArticleId><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M., Geddes J.R., Husain M., Luciano S., Harrison P.J. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: A retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8:416&#x2013;427. doi: 10.1016/S2215-0366(21)00084-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(21)00084-5</ArticleId><ArticleId IdType="pmc">PMC8023694</ArticleId><ArticleId IdType="pubmed">33836148</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkodaymi M.S., Omrani O.A., Fawzy N.A. Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: A systematic review and meta-analysis. Clin. Microbiol. Infect. 2022;28:657&#x2013;666. doi: 10.1016/j.cmi.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8812092</ArticleId><ArticleId IdType="pubmed">35124265</ArticleId></ArticleIdList></Reference><Reference><Citation>Premraj L., Kannapadi N.V., Briggs J. Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis. J. Neurol. Sci. 2022;434:120162. doi: 10.1016/j.jns.2022.120162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2022.120162</ArticleId><ArticleId IdType="pmc">PMC8798975</ArticleId><ArticleId IdType="pubmed">35121209</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Huang L., Wang Y. 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study. Lancet. 2021;397:220&#x2013;232. doi: 10.1016/S0140-6736(20)32656-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefanou M.I., Palaiodimou L., Bakola E. Neurological manifestations of long-COVID syndrome: A narrative review. Ther. Adv. Chronic Dis. 2022;13:20406223221076890. doi: 10.1177/20406223221076890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20406223221076890</ArticleId><ArticleId IdType="pmc">PMC8859684</ArticleId><ArticleId IdType="pubmed">35198136</ArticleId></ArticleIdList></Reference><Reference><Citation>Nersesjan V., Amiri M., Lebech A.M. Central and peripheral nervous system complications of COVID-19: A prospective tertiary center cohort with 3-month follow-up. J. Neurol. 2021;268:3086&#x2013;3104. doi: 10.1007/s00415-020-10380-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-10380-x</ArticleId><ArticleId IdType="pmc">PMC7803470</ArticleId><ArticleId IdType="pubmed">33438076</ArticleId></ArticleIdList></Reference><Reference><Citation>Beghi E., Giussani G., Westenberg E. Acute and post-acute neurological manifestations of COVID-19: Present findings, critical appraisal, and future directions. J. Neurol. 2022;269:2265&#x2013;2274. doi: 10.1007/s00415-021-10848-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10848-4</ArticleId><ArticleId IdType="pmc">PMC8528941</ArticleId><ArticleId IdType="pubmed">34674005</ArticleId></ArticleIdList></Reference><Reference><Citation>Estiri H., Strasser Z.H., Brat G.A. Evolving Phenotypes of non-hospitalized Patients that Indicate Long COVID. medRxiv. 2021 doi: 10.1186/s12916-021-02115-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-021-02115-0</ArticleId><ArticleId IdType="pmc">PMC8474909</ArticleId><ArticleId IdType="pubmed">34565368</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M., Dercon Q., Luciano S., Geddes J.R., Husain M., Harrison P.J. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021;18:e1003773. doi: 10.1371/journal.pmed.1003773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003773</ArticleId><ArticleId IdType="pmc">PMC8478214</ArticleId><ArticleId IdType="pubmed">34582441</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham E.L., Clark J.R., Orban Z.S., Lim P.H., Szymanski A.L., Taylor C., DiBiase R.M., Jia D.T., Balabanov R., Ho S.U., et al. Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized COVID-19 &#x201c;long haulers&#x201d;. Ann. Clin. Transl. Neurol. 2021;8:1073&#x2013;1085. doi: 10.1002/acn3.51350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51350</ArticleId><ArticleId IdType="pmc">PMC8108421</ArticleId><ArticleId IdType="pubmed">33755344</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai F., Tomasoni D., Falcinella C. Female gender is associated with long COVID syndrome: A prospective cohort study. Clin. Microbiol. Infect. 2022;28:611.e9&#x2013;611.e16. doi: 10.1016/j.cmi.2021.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.11.002</ArticleId><ArticleId IdType="pmc">PMC8575536</ArticleId><ArticleId IdType="pubmed">34763058</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill E., Mehta H., Sharma S. Risk Factors Associated with Post-Acute Sequelae of SARS-CoV-2 in an EHR Cohort: A National COVID Cohort Collaborative (N3C) Analysis as Part of the NIH RECOVER Program. medRxiv. 2022 doi: 10.1101/2022.08.15.22278603. medRxiv:2022.08.15.22278603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.08.15.22278603</ArticleId></ArticleIdList></Reference><Reference><Citation>Staffolani S., Iencinella V., Cimatti M., Tavio M. Long COVID-19 syndrome as a fourth phase of SARS-CoV-2 infection. Infez. Med. 2022;30:22&#x2013;29. doi: 10.53854/liim-3001-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.53854/liim-3001-3</ArticleId><ArticleId IdType="pmc">PMC8929740</ArticleId><ArticleId IdType="pubmed">35350258</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo S.M., Liu T.C., Motwani Y. Factors Associated with Post-Acute Sequelae of SARS-CoV-2 (PASC) After Diagnosis of Symptomatic COVID-19 in the Inpatient and Outpatient Setting in a Diverse Cohort. J. Gen. Intern. Med. 2022;37:1988&#x2013;1995. doi: 10.1007/s11606-022-07523-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-022-07523-3</ArticleId><ArticleId IdType="pmc">PMC8989256</ArticleId><ArticleId IdType="pubmed">35391623</ArticleId></ArticleIdList></Reference><Reference><Citation>Parotto M., Myatra S.N., Munblit D., Elhazmi A., Ranzani O.T., Herridge M.S. Recovery after prolonged ICU treatment in patients with COVID-19. Lancet Respir. Med. 2021;9:812&#x2013;814. doi: 10.1016/S2213-2600(21)00318-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00318-0</ArticleId><ArticleId IdType="pmc">PMC8280055</ArticleId><ArticleId IdType="pubmed">34273267</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham E.L., Koralnik I.J., Liotta E.M. Therapeutic Approaches to the Neurologic Manifestations of COVID-19. Neurotherapeutics. 2022;19:1435&#x2013;1466. doi: 10.1007/s13311-022-01267-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-022-01267-y</ArticleId><ArticleId IdType="pmc">PMC9302225</ArticleId><ArticleId IdType="pubmed">35861926</ArticleId></ArticleIdList></Reference><Reference><Citation>Iosifescu A.L., Hoogenboom W.S., Buczek A.J., Fleysher R., Duong T.Q. New-onset and persistent neurological and psychiatric sequelae of COVID-19 compared to influenza: A retrospective cohort study in a large New York City healthcare network. Int. J. Methods Psychiatr. Res. 2022;31:e1914. doi: 10.1002/mpr.1914.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mpr.1914</ArticleId><ArticleId IdType="pmc">PMC9349863</ArticleId><ArticleId IdType="pubmed">35706352</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y., Yuan D., Chen D.G. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185:881&#x2013;895. doi: 10.1016/j.cell.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherer P.E., Kirwan J.P., Rosen C.J. Post-acute sequelae of COVID-19: A metabolic perspective. Elife. 2022;11:e78200. doi: 10.7554/eLife.78200.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.78200</ArticleId><ArticleId IdType="pmc">PMC8942467</ArticleId><ArticleId IdType="pubmed">35318939</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., Deeks S.G. Early clues regarding the pathogenesis of long-COVID. Trends Immunol. 2022;43:268&#x2013;270. doi: 10.1016/j.it.2022.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2022.02.008</ArticleId><ArticleId IdType="pmc">PMC8901423</ArticleId><ArticleId IdType="pubmed">35272932</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Hu H., Fokaidis V. Identifying Contextual and Spatial Risk Factors for Post-Acute Sequelae of SARS-CoV-2 Infection: An EHR-Based Cohort Study from the RECOVER Program. medRxiv. 2022 doi: 10.1101/2022.10.13.22281010. medRxiv:2022.10.13.22281010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.10.13.22281010</ArticleId><ArticleId IdType="pmc">PMC9907788</ArticleId><ArticleId IdType="pubmed">36785842</ArticleId></ArticleIdList></Reference><Reference><Citation>Mainous A.G., III, Rooks B.J., Wu V., Orlando F.A. COVID-19 Post-acute Sequelae Among Adults: 12 Month Mortality Risk. Front. Med. 2021;8:2351. doi: 10.3389/fmed.2021.778434.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.778434</ArticleId><ArticleId IdType="pmc">PMC8671141</ArticleId><ArticleId IdType="pubmed">34926521</ArticleId></ArticleIdList></Reference><Reference><Citation>Meza-Torres B., Delanerolle G., Okusi C. Differences in Clinical Presentation with Long COVID after Community and Hospital Infection and Associations with All-Cause Mortality: English Sentinel Network Database Study. JMIR Public Health Surveill. 2022;8:e37668. doi: 10.2196/37668.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/37668</ArticleId><ArticleId IdType="pmc">PMC9384859</ArticleId><ArticleId IdType="pubmed">35605170</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao P., Liu J., Liu M. Effect of COVID-19 Vaccines on Reducing the Risk of Long COVID in the Real World: A Systematic Review and Meta-Analysis. Int. J. Environ. Res. Public Health. 2022;19:12422. doi: 10.3390/ijerph191912422.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph191912422</ArticleId><ArticleId IdType="pmc">PMC9566528</ArticleId><ArticleId IdType="pubmed">36231717</ArticleId></ArticleIdList></Reference><Reference><Citation>Strain W.D., Sherwood O., Banerjee A., Togt V., Hishmeh L., Rossman J. The Impact of COVID Vaccination on Symptoms of Long COVID: An International Survey of People with Lived Experience of Long COVID. Vaccines. 2022;10:652. doi: 10.3390/vaccines10050652.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10050652</ArticleId><ArticleId IdType="pmc">PMC9146071</ArticleId><ArticleId IdType="pubmed">35632408</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakhshandeh B., Sorboni S.G., Javanmard A.R., Mottaghi S.S., Mehrabi M.R., Sorouri F., Abbasi A., Jahanafrooz Z. Variants in ACE2; potential influences on virus infection and COVID-19 severity. Infect. Genet. Evol. J. Mol. Epidemiol. Evol. Genet. Infect. Dis. 2021;90:104773. doi: 10.1016/j.meegid.2021.104773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2021.104773</ArticleId><ArticleId IdType="pmc">PMC7886638</ArticleId><ArticleId IdType="pubmed">33607284</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf6;hlendick B., Sch&#xf6;nfelder K., Breuckmann K., Elsner C., Babel N., Balfanz P., Dahl E., Dreher M., Fistera D., Herbstreit F., et al. ACE2 polymorphism and susceptibility for SARS-CoV-2 infection and severity of COVID-19. Pharm. Genom. 2021;31:165&#x2013;171. doi: 10.1097/FPC.0000000000000436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/FPC.0000000000000436</ArticleId><ArticleId IdType="pmc">PMC8415730</ArticleId><ArticleId IdType="pubmed">34001841</ArticleId></ArticleIdList></Reference><Reference><Citation>Maglietta G., Diodati F., Puntoni M., Lazzarelli S., Marcomini B., Patrizi L., Caminiti C. Prognostic Factors for Post-COVID-19 Syndrome: A Systematic Review and Meta-Analysis. J. Clin. Med. 2022;11:1541. doi: 10.3390/jcm11061541.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11061541</ArticleId><ArticleId IdType="pmc">PMC8948827</ArticleId><ArticleId IdType="pubmed">35329867</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-de-Las-Pe&#xf1;as C., Arendt-Nielsen L., D&#xed;az-Gil G., G&#xf3;mez-Esquer F., Gil-Crujera A., G&#xf3;mez-S&#xe1;nchez S.M., Ambite-Quesada S., Palomar-Gallego M.A., Pellicer-Valero O.J., Giordano R. Genetic Association between ACE2 (rs2285666 and rs2074192) and TMPRSS2 (rs12329760 and rs2070788) Polymorphisms with Post-COVID Symptoms in Previously Hospitalized COVID-19 Survivors. Genes. 2022;13:1935. doi: 10.3390/genes13111935.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes13111935</ArticleId><ArticleId IdType="pmc">PMC9690177</ArticleId><ArticleId IdType="pubmed">36360172</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher T.M., Buchmeier M.J. Coronavirus spike proteins in viral entry and pathogenesis. Virology. 2001;279:371&#x2013;374. doi: 10.1006/viro.2000.0757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.2000.0757</ArticleId><ArticleId IdType="pmc">PMC7133764</ArticleId><ArticleId IdType="pubmed">11162792</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M., Kleine-Weber H., Schroeder S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181:271&#x2013;280. doi: 10.1016/j.cell.2020.02.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Heurich A., Hofmann-Winkler H., Gierer S., Liepold T., Jahn O., P&#xf6;hlmann S. TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein. J. Virol. 2014;88:1293&#x2013;1307. doi: 10.1128/JVI.02202-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02202-13</ArticleId><ArticleId IdType="pmc">PMC3911672</ArticleId><ArticleId IdType="pubmed">24227843</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W., Moore M.J., Vasilieva N. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450&#x2013;454. doi: 10.1038/nature02145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature02145</ArticleId><ArticleId IdType="pmc">PMC7095016</ArticleId><ArticleId IdType="pubmed">14647384</ArticleId></ArticleIdList></Reference><Reference><Citation>Song E., Zhang C., Israelow B. Neuroinvasion of SARS-CoV-2 in human and mouse brain. J. Exp. Med. 2021;218:e20202135. doi: 10.1084/jem.20202135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20202135</ArticleId><ArticleId IdType="pmc">PMC7808299</ArticleId><ArticleId IdType="pubmed">33433624</ArticleId></ArticleIdList></Reference><Reference><Citation>Meinhardt J., Radke J., Dittmayer C. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat. Neurosci. 2021;24:168&#x2013;175. doi: 10.1038/s41593-020-00758-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-020-00758-5</ArticleId><ArticleId IdType="pubmed">33257876</ArticleId></ArticleIdList></Reference><Reference><Citation>Brann D.H., Tsukahara T., Weinreb C. Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia. Sci. Adv. 2020;6:eabc5801. doi: 10.1126/sciadv.abc5801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abc5801</ArticleId><ArticleId IdType="pmc">PMC10715684</ArticleId><ArticleId IdType="pubmed">32937591</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandemirli S.G., Altundag A., Yildirim D., Tekcan Sanli D.E., Saatci O. Olfactory Bulb MRI and Paranasal Sinus CT Findings in Persistent COVID-19 Anosmia. Acad. Radiol. 2021;28:28&#x2013;35. doi: 10.1016/j.acra.2020.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.acra.2020.10.006</ArticleId><ArticleId IdType="pmc">PMC7571972</ArticleId><ArticleId IdType="pubmed">33132007</ArticleId></ArticleIdList></Reference><Reference><Citation>Butowt R., Meunier N., Bryche B., Bartheld C.S. The olfactory nerve is not a likely route to brain infection in COVID-19: A critical review of data from humans and animal models. Acta Neuropathol. 2021;141:809&#x2013;822. doi: 10.1007/s00401-021-02314-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-021-02314-2</ArticleId><ArticleId IdType="pmc">PMC8075028</ArticleId><ArticleId IdType="pubmed">33903954</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellegrini L., Albecka A., Mallery D.L. SARS-CoV-2 Infects the Brain Choroid Plexus and Disrupts the Blood-CSF Barrier in Human Brain Organoids. Cell Stem Cell. 2020;27:951&#x2013;961. doi: 10.1016/j.stem.2020.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2020.10.001</ArticleId><ArticleId IdType="pmc">PMC7553118</ArticleId><ArticleId IdType="pubmed">33113348</ArticleId></ArticleIdList></Reference><Reference><Citation>Muhl L., He L., Sun Y. The SARS-CoV-2 receptor ACE2 is expressed in mouse pericytes but not endothelial cells: Implications for COVID-19 vascular research. Stem Cell Rep. 2022;17:1089&#x2013;1104. doi: 10.1016/j.stemcr.2022.03.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2022.03.016</ArticleId><ArticleId IdType="pmc">PMC9022216</ArticleId><ArticleId IdType="pubmed">35452595</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis A., Frontera J., Placantonakis D.G., Galetta S., Balcer L., Melmed K.R. Cerebrospinal fluid from COVID-19 patients with olfactory/gustatory dysfunction: A review. Clin. Neurol. Neurosurg. 2021;207:106760. doi: 10.1016/j.clineuro.2021.106760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clineuro.2021.106760</ArticleId><ArticleId IdType="pmc">PMC8196517</ArticleId><ArticleId IdType="pubmed">34146842</ArticleId></ArticleIdList></Reference><Reference><Citation>Song E., Bartley C.M., Chow R.D. Divergent and self-reactive immune responses in the CNS of COVID-19 patients with neurological symptoms. Cell Rep. Med. 2021;2:100288. doi: 10.1016/j.xcrm.2021.100288.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100288</ArticleId><ArticleId IdType="pmc">PMC8091032</ArticleId><ArticleId IdType="pubmed">33969321</ArticleId></ArticleIdList></Reference><Reference><Citation>Matschke J., L&#xfc;tgehetmann M., Hagel C. Neuropathology of patients with COVID-19 in Germany: A post-mortem case series. Lancet Neurol. 2020;19:919&#x2013;929. doi: 10.1016/S1474-4422(20)30308-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30308-2</ArticleId><ArticleId IdType="pmc">PMC7535629</ArticleId><ArticleId IdType="pubmed">33031735</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakur K.T., Miller E.H., Glendinning M.D. COVID-19 neuropathology at Columbia University Irving Medical Center/New York Presbyterian Hospital. Brain. 2021;144:2696&#x2013;2708. doi: 10.1093/brain/awab148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab148</ArticleId><ArticleId IdType="pmc">PMC8083258</ArticleId><ArticleId IdType="pubmed">33856027</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang A.C., Kern F., Losada P.M. Dysregulation of brain and choroid plexus cell types in severe COVID-19 [published correction appears in Nature. Nature. 2021;595:565&#x2013;571. doi: 10.1038/s41586-021-03710-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03710-0</ArticleId><ArticleId IdType="pmc">PMC8400927</ArticleId><ArticleId IdType="pubmed">34153974</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Q., Zhou J., He Q. SARS-CoV-2 infection in the mouse olfactory system. Cell Discov. 2021;7:49. doi: 10.1038/s41421-021-00290-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-021-00290-1</ArticleId><ArticleId IdType="pmc">PMC8260584</ArticleId><ArticleId IdType="pubmed">34230457</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsivgoulis G., Fragkou P.C., Lachanis S. Olfactory bulb and mucosa abnormalities in persistent COVID-19-induced anosmia: A magnetic resonance imaging study. Eur. J. Neurol. 2021;28:e6&#x2013;e8. doi: 10.1111/ene.14537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14537</ArticleId><ArticleId IdType="pubmed">32939911</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamagishi M., Hasegawa S., Nakano Y. Examination and classification of human olfactory mucosa in patients with clinical olfactory disturbances. Arch. Otorhinolaryngol. 1988;245:316&#x2013;320. doi: 10.1007/BF00464640.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00464640</ArticleId><ArticleId IdType="pubmed">3245805</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaira L.A., Hopkins C., Sandison A. Olfactory epithelium histopathological findings in long-term coronavirus disease 2019 related anosmia. J. Laryngol. Otol. 2020;134:1123&#x2013;1127. doi: 10.1017/S0022215120002455.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0022215120002455</ArticleId><ArticleId IdType="pmc">PMC7729153</ArticleId><ArticleId IdType="pubmed">33190655</ArticleId></ArticleIdList></Reference><Reference><Citation>de Melo G.D., Lazarini F., Levallois S., Hautefort C., Michel V., Larrous F., Verillaud B., Aparicio C., Wagner S., Gheusi G., et al. COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters. Sci. Transl. Med. 2021;13:eabf8396. doi: 10.1126/scitranslmed.abf8396.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abf8396</ArticleId><ArticleId IdType="pmc">PMC8158965</ArticleId><ArticleId IdType="pubmed">33941622</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y., Guo C., Tang L. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. Lancet Gastroenterol. Hepatol. 2020;5:434&#x2013;435. doi: 10.1016/S2468-1253(20)30083-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(20)30083-2</ArticleId><ArticleId IdType="pmc">PMC7158584</ArticleId><ArticleId IdType="pubmed">32199469</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J., Xiao J., Sun R. Prolonged Persistence of SARS-CoV-2 RNA in Body Fluids. Emerg. Infect. Dis. 2020;26:1834&#x2013;1838. doi: 10.3201/eid2608.201097.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2608.201097</ArticleId><ArticleId IdType="pmc">PMC7392422</ArticleId><ArticleId IdType="pubmed">32383638</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo T., Zhang F., Lui G.C.Y. Alterations in Gut Microbiota of Patients with COVID-19 During Time of Hospitalization. Gastroenterology. 2020;159:944&#x2013;955. doi: 10.1053/j.gastro.2020.05.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.05.048</ArticleId><ArticleId IdType="pmc">PMC7237927</ArticleId><ArticleId IdType="pubmed">32442562</ArticleId></ArticleIdList></Reference><Reference><Citation>Quigley E.M.M. Microbiota-Brain-Gut Axis and Neurodegenerative Diseases. Curr. Neurol. Neurosci. Rep. 2017;17:94. doi: 10.1007/s11910-017-0802-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11910-017-0802-6</ArticleId><ArticleId IdType="pubmed">29039142</ArticleId></ArticleIdList></Reference><Reference><Citation>Nataf S., Pays L. Molecular Insights into SARS-CoV2-Induced Alterations of the Gut/Brain Axis. Int. J. Mol. Sci. 2021;22:10440. doi: 10.3390/ijms221910440.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms221910440</ArticleId><ArticleId IdType="pmc">PMC8508788</ArticleId><ArticleId IdType="pubmed">34638785</ArticleId></ArticleIdList></Reference><Reference><Citation>Daulagala S.W.P.L., Noordeen F. Epidemiology and factors influencing varicella infections in tropical countries including Sri Lanka. Virusdisease. 2018;29:277&#x2013;284. doi: 10.1007/s13337-018-0459-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13337-018-0459-z</ArticleId><ArticleId IdType="pmc">PMC6111959</ArticleId><ArticleId IdType="pubmed">30159361</ArticleId></ArticleIdList></Reference><Reference><Citation>Smatti M.K., Al-Sadeq D.W., Ali N.H., Pintus G., Abou-Saleh H., Nasrallah G.K. Epstein-Barr Virus Epidemiology, Serology, and Genetic Variability of LMP-1 Oncogene Among Healthy Population: An Update. Front. Oncol. 2018;8:211. doi: 10.3389/fonc.2018.00211.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2018.00211</ArticleId><ArticleId IdType="pmc">PMC6008310</ArticleId><ArticleId IdType="pubmed">29951372</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng M., Zhang S., Dong X., Sun W., Deng Y., Li W., Li R., Annane D., Wu Z., Chen D. COVID-19 associated EBV reactivation and effects of ganciclovir treatment. Immun. Inflamm. Dis. 2022;10:e597. doi: 10.1002/iid3.597.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.597</ArticleId><ArticleId IdType="pmc">PMC8959425</ArticleId><ArticleId IdType="pubmed">35349757</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold J.E., Okyay R.A., Licht W.E., Hurley D.J. Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation. Pathogens. 2021;10:763. doi: 10.3390/pathogens10060763.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens10060763</ArticleId><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="pubmed">34204243</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Pablos M., Paiva B., Montero-Mateo R., Garcia N., Zabaleta A. Epstein-Barr Virus and the Origin of Myalgic Encephalomyelitis or Chronic Fatigue Syndrome. Front. Immunol. 2021;12:656797. doi: 10.3389/fimmu.2021.656797.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.656797</ArticleId><ArticleId IdType="pmc">PMC8634673</ArticleId><ArticleId IdType="pubmed">34867935</ArticleId></ArticleIdList></Reference><Reference><Citation>Monje M., Iwasaki A. The neurobiology of long COVID. Neuron. 2022;110:3484&#x2013;3496. doi: 10.1016/j.neuron.2022.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2022.10.006</ArticleId><ArticleId IdType="pmc">PMC9537254</ArticleId><ArticleId IdType="pubmed">36288726</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J., Wood J., Jaycox J., Lu P., Dhodapkar R.M., Gehlhausen J.R., Tabachnikova A., Tabacof L., Malik A.A., Kamath K., et al. Distinguishing features of Long COVID identified through immune profiling. medRxiv. 2022 doi: 10.1101/2022.08.09.22278592. medRxiv:2022.08.09.22278592.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.08.09.22278592</ArticleId><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Reviejo R., Tejada S., Adebanjo G.A.R., Chello C., Machado M.C., Parisella F.R., Campins M., Tammaro A., Rello J. Varicella-Zoster virus reactivation following severe acute respiratory syndrome coronavirus 2 vaccination or infection: New insights. Eur. J. Intern. Med. 2022;104:73&#x2013;79. doi: 10.1016/j.ejim.2022.07.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2022.07.022</ArticleId><ArticleId IdType="pmc">PMC9340059</ArticleId><ArticleId IdType="pubmed">35931613</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen W., Chen C., Tang J. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: A meta-analysis. Ann. Med. 2022;54:516&#x2013;523. doi: 10.1080/07853890.2022.2034936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2022.2034936</ArticleId><ArticleId IdType="pmc">PMC8820829</ArticleId><ArticleId IdType="pubmed">35118917</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond J., Leister-Tebbe H., Gardner A. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with COVID-19. N. Engl. J. Med. 2022;386:1397&#x2013;1408. doi: 10.1056/NEJMoa2118542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118542</ArticleId><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawood A.A. The efficacy of Paxlovid against COVID-19 is the result of the tight molecular docking between Mpro and antiviral drugs (nirmatrelvir and ritonavir) [published online ahead of print, 2 November 2022] Adv. Med. Sci. 2022;68:1&#x2013;9. doi: 10.1016/j.advms.2022.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.advms.2022.10.001</ArticleId><ArticleId IdType="pmc">PMC9626444</ArticleId><ArticleId IdType="pubmed">36368287</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Choi T., Al-Aly Z. Nirmatrelvir and the Risk of Post-Acute Sequelae of COVID-19. Infectious Diseases (except HIV/AIDS) medRixv. 2022 doi: 10.1101/2022.11.03.22281783.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.11.03.22281783</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh C.V., Jain S., Parveen S. The outcome of fluticasone nasal spray on anosmia and triamcinolone oral paste in dysgeusia in COVID-19 patients. Am. J. Otolaryngol. 2021;42:102892. doi: 10.1016/j.amjoto.2020.102892.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjoto.2020.102892</ArticleId><ArticleId IdType="pmc">PMC7972940</ArticleId><ArticleId IdType="pubmed">33493729</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelalim A.A., Mohamady A.A., Elsayed R.A., Elawady M.A., Ghallab A.F. Corticosteroid nasal spray for recovery of smell sensation in COVID-19 patients: A randomized controlled trial. Am. J. Otolaryngol. 2021;42:102884. doi: 10.1016/j.amjoto.2020.102884.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjoto.2020.102884</ArticleId><ArticleId IdType="pmc">PMC7836546</ArticleId><ArticleId IdType="pubmed">33429174</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Kelly B., Vidal L., McHugh T., Woo J., Avramovic G., Lambert J.S. Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study. Brain Behav. Immun. Health. 2022;24:100485. doi: 10.1016/j.bbih.2022.100485.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbih.2022.100485</ArticleId><ArticleId IdType="pmc">PMC9250701</ArticleId><ArticleId IdType="pubmed">35814187</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamad S.A., Badawi A.M., Mansour H.F. Insulin fast-dissolving film for intranasal delivery via olfactory region, a promising approach for the treatment of anosmia in COVID-19 patients: Design, in-vitro characterization and clinical evaluation. Int. J. Pharm. 2021;601:120600. doi: 10.1016/j.ijpharm.2021.120600.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2021.120600</ArticleId><ArticleId IdType="pubmed">33862126</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezaeian A. Effect of Intranasal Insulin on Olfactory Recovery in Patients with Hyposmia: A Randomized Clinical Trial. Otolaryngol. Head Neck Surg. 2018;158:1134&#x2013;1139. doi: 10.1177/0194599818764624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0194599818764624</ArticleId><ArticleId IdType="pubmed">29557250</ArticleId></ArticleIdList></Reference><Reference><Citation>Glynne P., Tahmasebi N., Gant V., Gupta R. Long COVID following mild SARS-CoV-2 infection: Characteristic T cell alterations and response to antihistamines. J. Investig. Med. Off. Publ. Am. Fed. Clin. Res. 2022;70:61&#x2013;67. doi: 10.1136/jim-2021-002051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jim-2021-002051</ArticleId><ArticleId IdType="pmc">PMC8494538</ArticleId><ArticleId IdType="pubmed">34611034</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen L.C., Yang D., Nicolaescu V., Best T.J., Ohtsuki T., Chen S.N., Friesen J.B., Drayman N., Mohamed A., Dann C., et al. Cannabidiol Inhibits SARS-CoV-2 Replication and Promotes the Host Innate Immune Response. bioRxiv. 2021 doi: 10.1101/2021.03.10.432967. bioRxiv:2021.03.10.432967.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.10.432967</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito G., Pesce M., Seguella L., Sanseverino W., Lu J., Corpetti C., Sarnelli G. The potential of cannabidiol in the COVID-19 pandemic. Br. J. Pharmacol. 2020;177:4967&#x2013;4970. doi: 10.1111/bph.15157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15157</ArticleId><ArticleId IdType="pmc">PMC7300643</ArticleId><ArticleId IdType="pubmed">32519753</ArticleId></ArticleIdList></Reference><Reference><Citation>Campos A.C., Foga&#xe7;a M.V., Sonego A.B., Guimar&#xe3;es F.S. Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacol. Res. 2016;112:119&#x2013;127. doi: 10.1016/j.phrs.2016.01.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2016.01.033</ArticleId><ArticleId IdType="pubmed">26845349</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo A., Tol&#xf3;n M.R., Fern&#xe1;ndez-Ruiz J., Romero J., Martinez-Orgado J. The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB(2) and adenosine receptors. Neurobiol. Dis. 2010;37:434&#x2013;440. doi: 10.1016/j.nbd.2009.10.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2009.10.023</ArticleId><ArticleId IdType="pubmed">19900555</ArticleId></ArticleIdList></Reference><Reference><Citation>Degerman E., Rauch U., Lindberg S., Caye-Thomasen P., Hultg&#xe5;rdh A., Magnusson M. Expression of insulin signalling components in the sensory epithelium of the human saccule. Cell Tissue Res. 2013;352:469&#x2013;478. doi: 10.1007/s00441-013-1614-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00441-013-1614-x</ArticleId><ArticleId IdType="pubmed">23584706</ArticleId></ArticleIdList></Reference><Reference><Citation>Khani E., Khiali S., Beheshtirouy S., Entezari-Maleki T. Potential pharmacologic treatments for COVID-19 smell and taste loss: A comprehensive review. Eur. J. Pharmacol. 2021;912:174582. doi: 10.1016/j.ejphar.2021.174582.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2021.174582</ArticleId><ArticleId IdType="pmc">PMC8524700</ArticleId><ArticleId IdType="pubmed">34678243</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan F.J., Hope C.M., Masavuli M.G. Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection. BMC Med. 2022;20:26. doi: 10.1186/s12916-021-02228-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-021-02228-6</ArticleId><ArticleId IdType="pmc">PMC8758383</ArticleId><ArticleId IdType="pubmed">35027067</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C., Darley D.R., Wilson D.B. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat. Immunol. 2022;23:210&#x2013;216. doi: 10.1038/s41590-021-01113-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Queiroz M.A.F., Neves P.F.M.d., Lima S.S., Lopes J.D., Torres M.K., Vallinoto I.M., Bichara C.D., Santos E.F., de Brito M.T., Da Silva A.L., et al. Cytokine Profiles Associated with Acute COVID-19 and Long COVID-19 Syndrome. Front. Cell. Infect. Microbiol. 2022;12:922422. doi: 10.3389/fcimb.2022.922422.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2022.922422</ArticleId><ArticleId IdType="pmc">PMC9279918</ArticleId><ArticleId IdType="pubmed">35846757</ArticleId></ArticleIdList></Reference><Reference><Citation>Arun S., Storan A., Myers B. Mast cell activation syndrome and the link with long COVID. Br. J. Hosp. Med. 2022;83:1&#x2013;10. doi: 10.12968/hmed.2022.0123.</Citation><ArticleIdList><ArticleId IdType="doi">10.12968/hmed.2022.0123</ArticleId><ArticleId IdType="pubmed">35938771</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstock L.B., Brook J.B., Walters A.S., Goris A., Afrin L.B., Molderings G.J. Mast cell activation symptoms are prevalent in Long-COVID. Int. J. Infect. Dis. 2021;112:217&#x2013;226. doi: 10.1016/j.ijid.2021.09.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.09.043</ArticleId><ArticleId IdType="pmc">PMC8459548</ArticleId><ArticleId IdType="pubmed">34563706</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., Deitchman A.N., Torres L. Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Rep. 2021;36:109518. doi: 10.1016/j.celrep.2021.109518.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.109518</ArticleId><ArticleId IdType="pmc">PMC8342976</ArticleId><ArticleId IdType="pubmed">34358460</ArticleId></ArticleIdList></Reference><Reference><Citation>Vibholm L.K., Nielsen S.S.F., Pahus M.H. SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses. EBioMedicine. 2021;64:103230. doi: 10.1016/j.ebiom.2021.103230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103230</ArticleId><ArticleId IdType="pmc">PMC7847186</ArticleId><ArticleId IdType="pubmed">33530000</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson B.K., Francisco E.B., Yogendra R. Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-Infection. Front. Immunol. 2022;12:5526. doi: 10.3389/fimmu.2021.746021.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.746021</ArticleId><ArticleId IdType="pmc">PMC8784688</ArticleId><ArticleId IdType="pubmed">35082777</ArticleId></ArticleIdList></Reference><Reference><Citation>Etter M.M., Martins T.A., Kulsvehagen L., P&#xf6;ssnecker E., Duchemin W., Hogan S., Sanabria-Diaz G., M&#xfc;ller J., Chiappini A., Rychen J., et al. Severe Neuro-COVID is associated with peripheral immune signatures, autoimmunity and neurodegeneration: A prospective cross-sectional study. Nat. Commun. 2022;13:6777. doi: 10.1038/s41467-022-34068-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-34068-0</ArticleId><ArticleId IdType="pmc">PMC9645766</ArticleId><ArticleId IdType="pubmed">36351919</ArticleId></ArticleIdList></Reference><Reference><Citation>Heming M., Li X., R&#xe4;uber S. Neurological Manifestations of COVID-19 Feature T Cell Exhaustion and Dedifferentiated Monocytes in Cerebrospinal Fluid. Immunity. 2021;54:164&#x2013;175. doi: 10.1016/j.immuni.2020.12.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.12.011</ArticleId><ArticleId IdType="pmc">PMC7831653</ArticleId><ArticleId IdType="pubmed">33382973</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L., Dyer A.H., Naughton A. Longitudinal Analysis of COVID-19 Patients Shows Age-Associated T Cell Changes Independent of Ongoing Ill-Health. Front. Immunol. 2021;12:1593. doi: 10.3389/fimmu.2021.676932.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.676932</ArticleId><ArticleId IdType="pmc">PMC8138306</ArticleId><ArticleId IdType="pubmed">34025675</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi J.S., Cox M.A., Zajac A.J. T-cell exhaustion: Characteristics, causes and conversion. Immunology. 2010;129:474&#x2013;481. doi: 10.1111/j.1365-2567.2010.03255.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2567.2010.03255.x</ArticleId><ArticleId IdType="pmc">PMC2842494</ArticleId><ArticleId IdType="pubmed">20201977</ArticleId></ArticleIdList></Reference><Reference><Citation>Visvabharathy L., Hanson B., Orban Z. Neuro-COVID long-haulers exhibit broad dysfunction in T cell memory generation and responses to vaccination. medRxiv. 2021 doi: 10.1101/2021.08.08.21261763. medRxiv:2021(08.08.21261763)</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.08.08.21261763</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwabenland M., Sali&#xe9; H., Tanevski J. Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T-cell interactions. Immunity. 2021;54:1594&#x2013;1610. doi: 10.1016/j.immuni.2021.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.06.002</ArticleId><ArticleId IdType="pmc">PMC8188302</ArticleId><ArticleId IdType="pubmed">34174183</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Fu L., Gonzales D.M., Lavi E. Coronavirus neurovirulence correlates with the ability of the virus to induce proinflammatory cytokine signals from astrocytes and microglia. J. Virol. 2004;78:3398&#x2013;3406. doi: 10.1128/JVI.78.7.3398-3406.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.78.7.3398-3406.2004</ArticleId><ArticleId IdType="pmc">PMC371061</ArticleId><ArticleId IdType="pubmed">15016862</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G., Hohberger B., Wenzel K. Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J. Transl. Autoimmun. 2021;4:100100. doi: 10.1016/j.jtauto.2021.100100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2021.100100</ArticleId><ArticleId IdType="pmc">PMC8049853</ArticleId><ArticleId IdType="pubmed">33880442</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang S.E., Feng A., Meng W. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat. Commun. 2021;12:5417. doi: 10.1038/s41467-021-25509-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-25509-3</ArticleId><ArticleId IdType="pmc">PMC8440763</ArticleId><ArticleId IdType="pubmed">34521836</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthur J.M., Forrest J.C., Boehme K.W. Development of ACE2 autoantibodies after SARS-CoV-2 infection. PLoS ONE. 2021;16:e0257016. doi: 10.1371/journal.pone.0257016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0257016</ArticleId><ArticleId IdType="pmc">PMC8415618</ArticleId><ArticleId IdType="pubmed">34478478</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacchi M.C., Tamiazzo S., Stobbione P. SARS-CoV-2 infection as a trigger of autoimmune response. Clin. Transl. Sci. 2021;14:898&#x2013;907. doi: 10.1111/cts.12953.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cts.12953</ArticleId><ArticleId IdType="pmc">PMC8212749</ArticleId><ArticleId IdType="pubmed">33306235</ArticleId></ArticleIdList></Reference><Reference><Citation>Allahyari F., Hosseinzadeh R., Nejad J.H., Heiat M., Ranjbar R. A case report of simultaneous autoimmune and COVID-19 encephalitis. J. Neurovirol. 2021;27:504&#x2013;506. doi: 10.1007/s13365-021-00978-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13365-021-00978-w</ArticleId><ArticleId IdType="pmc">PMC8075017</ArticleId><ArticleId IdType="pubmed">33904138</ArticleId></ArticleIdList></Reference><Reference><Citation>Burr T., Barton C., Doll E., Lakhotia A., Sweeney M. N-Methyl-d-Aspartate Receptor Encephalitis Associated with COVID-19 Infection in a Toddler. Pediatr. Neurol. 2021;114:75&#x2013;76. doi: 10.1016/j.pediatrneurol.2020.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pediatrneurol.2020.10.002</ArticleId><ArticleId IdType="pmc">PMC7546658</ArticleId><ArticleId IdType="pubmed">33246132</ArticleId></ArticleIdList></Reference><Reference><Citation>Flannery P., Yang I., Keyvani M., Sakoulas G. Acute Psychosis Due to Anti-N-Methyl D-Aspartate Receptor Encephalitis Following COVID-19 Vaccination: A Case Report. Front. Neurol. 2021;12:764197. doi: 10.3389/fneur.2021.764197.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.764197</ArticleId><ArticleId IdType="pmc">PMC8599934</ArticleId><ArticleId IdType="pubmed">34803896</ArticleId></ArticleIdList></Reference><Reference><Citation>Durovic E., Bien C., Bien C.G., Isenmann S. MOG antibody-associated encephalitis secondary to COVID-19: Case report. BMC Neurol. 2021;21:414. doi: 10.1186/s12883-021-02449-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-021-02449-5</ArticleId><ArticleId IdType="pmc">PMC8549422</ArticleId><ArticleId IdType="pubmed">34706651</ArticleId></ArticleIdList></Reference><Reference><Citation>da Costa M.D., Rato M.L., Cruz D., Valadas A., Antunes A.P., Albuquerque L. Longitudinally extensive transverse myelitis with anti-myelin oligodendrocyte glycoprotein antibodies following SARS-CoV-2 infection. J. Neuroimmunol. 2021;361:577739. doi: 10.1016/j.jneuroim.2021.577739.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2021.577739</ArticleId><ArticleId IdType="pmc">PMC8492014</ArticleId><ArticleId IdType="pubmed">34628134</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff M.C., Walker T.A., Truong A.D. Evidence of Persisting Autoreactivity in Post-Acute Sequelae of SARS-CoV-2 Infection. medRxiv. 2021 doi: 10.1101/2021.09.21.21263845. medRxiv:2021.09.21.21263845.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.09.21.21263845</ArticleId></ArticleIdList></Reference><Reference><Citation>Paterson R.W., Brown R.L., Benjamin L. The emerging spectrum of COVID-19 neurology: Clinical, radiological and laboratory findings. Brain. 2020;143:3104&#x2013;3120. doi: 10.1093/brain/awaa240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa240</ArticleId><ArticleId IdType="pmc">PMC7454352</ArticleId><ArticleId IdType="pubmed">32637987</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., Anglin K., Durstenfeld M.S. Effect of Oral Nirmatrelvir on Long COVID Symptoms: 4 Cases and Rationale for Systematic Studies. Pathog. Immun. 2022;7:95&#x2013;103. doi: 10.20411/pai.v7i1.518.</Citation><ArticleIdList><ArticleId IdType="doi">10.20411/pai.v7i1.518</ArticleId><ArticleId IdType="pmc">PMC9254867</ArticleId><ArticleId IdType="pubmed">35800257</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D., Bermingham C., Pouwels K.B. Trajectory of long covid symptoms after covid-19 vaccination: Community based cohort study. BMJ. 2022;377:e069676. doi: 10.1136/bmj-2021-069676.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-069676</ArticleId><ArticleId IdType="pmc">PMC9115603</ArticleId><ArticleId IdType="pubmed">35584816</ArticleId></ArticleIdList></Reference><Reference><Citation>Dale A.M., Strickland J., Gardner B., Symanzik J., Evanoff B.A. Assessing agreement of self-reported and observed physical exposures of the upper extremity. Int. J. Occup. Environ. Health. 2010;16:1&#x2013;10. doi: 10.1179/oeh.2010.16.1.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/oeh.2010.16.1.1</ArticleId><ArticleId IdType="pmc">PMC3579613</ArticleId><ArticleId IdType="pubmed">20166314</ArticleId></ArticleIdList></Reference><Reference><Citation>Spuch C., L&#xf3;pez-Garc&#xed;a M., Rivera-Baltan&#xe1;s T. Efficacy and Safety of Lithium Treatment in SARS-CoV-2 Infected Patients. Front. Pharmacol. 2022;13:1081. doi: 10.3389/fphar.2022.850583.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.850583</ArticleId><ArticleId IdType="pmc">PMC9046673</ArticleId><ArticleId IdType="pubmed">35496309</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher B., Barone F., Jobling K. Syndrome Oeor 132 Ofipwps. Results of a Phase II Randomised, Double-Blind, Placebo-Controlled, Proof of Concept Study. Ann. Rheum. Dis. 2019;78:177. doi: 10.1136/annrheumdis-2019-eular.3098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-eular.3098</ArticleId></ArticleIdList></Reference><Reference><Citation>Wenzel J., Lampe J., M&#xfc;ller-Fielitz H. The SARS-CoV-2 main protease Mpro causes microvascular brain pathology by cleaving NEMO in brain endothelial cells. Nat. Neurosci. 2021;24:1522&#x2013;1533. doi: 10.1038/s41593-021-00926-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-021-00926-1</ArticleId><ArticleId IdType="pmc">PMC8553622</ArticleId><ArticleId IdType="pubmed">34675436</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckingham S.C., Campbell S.L., Haas B.R., Montana V., Robel S., Ogunrinu T., Sontheimer H. Glutamate release by primary brain tumors induces epileptic activity. Nat. Med. 2011;17:1269&#x2013;1274. doi: 10.1038/nm.2453.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2453</ArticleId><ArticleId IdType="pmc">PMC3192231</ArticleId><ArticleId IdType="pubmed">21909104</ArticleId></ArticleIdList></Reference><Reference><Citation>Verkhratsky A., Parpura V. Astrogliopathology in neurological, neurodevelopmental and psychiatric disorders. Neurobiol. Dis. 2016;85:254&#x2013;261. doi: 10.1016/j.nbd.2015.03.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2015.03.025</ArticleId><ArticleId IdType="pmc">PMC4592688</ArticleId><ArticleId IdType="pubmed">25843667</ArticleId></ArticleIdList></Reference><Reference><Citation>Fern&#xe1;ndez-Casta&#xf1;eda A., Lu P., Geraghty A.C. Mild respiratory SARS-CoV-2 infection can cause multi-lineage cellular dysregulation and myelin loss in the brain. bioRxiv. 2022 doi: 10.1101/2022.01.07.475453. bioRxiv:2022(01.07.475453)</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.01.07.475453</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira A.O., Malwade S., Rufino de Sousa N., Goparaju S.K., Gracias J., Orhan F., Steponaviciute L., Schalling M., Sheridan S.D., Perlis R.H., et al. SARS-CoV-2 promotes microglial synapse elimination in human brain organoids. Mol. Psychiatry. 2022;27:3939&#x2013;3950. doi: 10.1038/s41380-022-01786-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-022-01786-2</ArticleId><ArticleId IdType="pmc">PMC9533278</ArticleId><ArticleId IdType="pubmed">36198765</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E., Vlok M., Venter C. Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc. Diabetol. 2021;20:172. doi: 10.1186/s12933-021-01359-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-021-01359-7</ArticleId><ArticleId IdType="pmc">PMC8381139</ArticleId><ArticleId IdType="pubmed">34425843</ArticleId></ArticleIdList></Reference><Reference><Citation>Grobbelaar L.M., Venter C., Vlok M. SARS-CoV-2 spike protein S1 induces fibrin(ogen) resistant to fibrinolysis: Implications for microclot formation in COVID-19. Biosci. Rep. 2021;41:BSR20210611. doi: 10.1042/BSR20210611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BSR20210611</ArticleId><ArticleId IdType="pmc">PMC8380922</ArticleId><ArticleId IdType="pubmed">34328172</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu J.K., Sozmen E.G., Dixit K. SARS-CoV-2 Spike Protein Induces Abnormal Inflammatory Blood Clots Neutralized by Fibrin Immunotherapy. bioRxiv. 2021 doi: 10.1101/2021.10.12.464152. bioRxiv:2021.10.12.464152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.10.12.464152</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouck E.G., Denorme F., Holle L.A. COVID-19 and Sepsis Are Associated with Different Abnormalities in Plasma Procoagulant and Fibrinolytic Activity. Arter. Thromb. Vasc. Biol. 2021;41:401&#x2013;414. doi: 10.1161/ATVBAHA.120.315338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.120.315338</ArticleId><ArticleId IdType="pmc">PMC7942774</ArticleId><ArticleId IdType="pubmed">33196292</ArticleId></ArticleIdList></Reference><Reference><Citation>Jana A.K., Greenwood A.B., Hansmann U.H.E. Presence of a SARS-CoV-2 protein enhances Amyloid Formation of Serum Amyloid A. bioRxiv. 2021 doi: 10.1021/acs.jpcb.1c04871. bioRxiv:2021(05.18.444723)</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jpcb.1c04871</ArticleId><ArticleId IdType="pmc">PMC8369982</ArticleId><ArticleId IdType="pubmed">34370466</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Y., Estes S.K., Ali R.A. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci. Transl. Med. 2020;12:eabd3876. doi: 10.1126/scitranslmed.abd3876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abd3876</ArticleId><ArticleId IdType="pmc">PMC7724273</ArticleId><ArticleId IdType="pubmed">33139519</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung M.L., Tan B., Cherian R., Chandra B. Anti-phospholipid syndrome and COVID-19 thrombosis: Connecting the dots. Rheumatol. Adv. Pract. 2021;5:rkaa081. doi: 10.1093/rap/rkaa081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rap/rkaa081</ArticleId><ArticleId IdType="pmc">PMC7882149</ArticleId><ArticleId IdType="pubmed">33615129</ArticleId></ArticleIdList></Reference><Reference><Citation>Passos F.R.S., Heimfarth L., Monteiro B.S. Oxidative stress and inflammatory markers in patients with COVID-19: Potential role of RAGE, HMGB1, GFAP and COX-2 in disease severity. Int. Immunopharmacol. 2022;104:108502. doi: 10.1016/j.intimp.2021.108502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2021.108502</ArticleId><ArticleId IdType="pmc">PMC8730710</ArticleId><ArticleId IdType="pubmed">35063743</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogarty H., Townsend L., Morrin H. Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J. Thromb. Haemost. 2021;19:2546&#x2013;2553. doi: 10.1111/jth.15490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15490</ArticleId><ArticleId IdType="pmc">PMC8420256</ArticleId><ArticleId IdType="pubmed">34375505</ArticleId></ArticleIdList></Reference><Reference><Citation>Poyatos P., Luque N., Eizaguirre S. Post-COVID-19 patients show an increased endothelial progenitor cell production. Transl. Res. 2022;243:14&#x2013;20. doi: 10.1016/j.trsl.2022.01.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2022.01.004</ArticleId><ArticleId IdType="pmc">PMC8785258</ArticleId><ArticleId IdType="pubmed">35085821</ArticleId></ArticleIdList></Reference><Reference><Citation>Christensen R.H., Berg R.M.G. Vascular Inflammation as a Therapeutic Target in COVID-19 &#x201c;Long Haulers&#x201d;: HIITing the Spot? Front. Cardiovasc. Med. 2021;8:187. doi: 10.3389/fcvm.2021.643626.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2021.643626</ArticleId><ArticleId IdType="pmc">PMC8044938</ArticleId><ArticleId IdType="pubmed">33869305</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee M.H., Perl D.P., Steiner J. Neurovascular injury with complement activation and inflammation in COVID-19. Brain. 2022;145:2555&#x2013;2568. doi: 10.1093/brain/awac151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awac151</ArticleId><ArticleId IdType="pmc">PMC9278212</ArticleId><ArticleId IdType="pubmed">35788639</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambadiari V., Mitrakou A., Kountouri A. Association of COVID-19 with impaired endothelial glycocalyx, vascular function and myocardial deformation 4 months after infection. Eur. J. Heart Fail. 2021;23:1916&#x2013;1926. doi: 10.1002/ejhf.2326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejhf.2326</ArticleId><ArticleId IdType="pmc">PMC8426810</ArticleId><ArticleId IdType="pubmed">34415085</ArticleId></ArticleIdList></Reference><Reference><Citation>Buzhdygan T.P., DeOre B.J., Baldwin-Leclair A. The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in-vitro models of the human blood-brain barrier. Neurobiol. Dis. 2020;146:105131. doi: 10.1016/j.nbd.2020.105131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.105131</ArticleId><ArticleId IdType="pmc">PMC7547916</ArticleId><ArticleId IdType="pubmed">33053430</ArticleId></ArticleIdList></Reference><Reference><Citation>Osiaevi I., Schulze A., Evers G. Persistent capillary rarefication in long COVID syndrome [published online ahead of print, 2022 Aug 11. Angiogenesis. 2022;26:53&#x2013;61. doi: 10.1007/s10456-022-09850-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10456-022-09850-9</ArticleId><ArticleId IdType="pmc">PMC9366128</ArticleId><ArticleId IdType="pubmed">35951203</ArticleId></ArticleIdList></Reference><Reference><Citation>Guedj E., Campion J.Y., Dudouet P. 18F-FDG brain PET hypometabolism in patients with long COVID. Eur. J. Nucl. Med. Mol. Imaging. 2021;48:2823&#x2013;2833. doi: 10.1007/s00259-021-05215-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-021-05215-4</ArticleId><ArticleId IdType="pmc">PMC7837643</ArticleId><ArticleId IdType="pubmed">33501506</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong S.J. Persistent Brainstem Dysfunction in Long-COVID: A Hypothesis. ACS Chem. Neurosci. 2021;12:573&#x2013;580. doi: 10.1021/acschemneuro.0c00793.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.0c00793</ArticleId><ArticleId IdType="pubmed">33538586</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnden L.R., Shan Z.Y., Staines D.R. Hyperintense sensorimotor T1 spin echo MRI is associated with brainstem abnormality in chronic fatigue syndrome. Neuroimage Clin. 2018;20:102&#x2013;109. doi: 10.1016/j.nicl.2018.07.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2018.07.011</ArticleId><ArticleId IdType="pmc">PMC6309570</ArticleId><ArticleId IdType="pubmed">30497131</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnden L.R., Crouch B., Kwiatek R. A brain MRI study of chronic fatigue syndrome: Evidence of brainstem dysfunction and altered homeostasis. NMR Biomed. 2011;24:1302&#x2013;1312. doi: 10.1002/nbm.1692.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/nbm.1692</ArticleId><ArticleId IdType="pmc">PMC4369126</ArticleId><ArticleId IdType="pubmed">21560176</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnden L.R., Shan Z.Y., Staines D.R. Intra brainstem connectivity is impaired in chronic fatigue syndrome. Neuroimage Clin. 2019;24:102045. doi: 10.1016/j.nicl.2019.102045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2019.102045</ArticleId><ArticleId IdType="pmc">PMC6835065</ArticleId><ArticleId IdType="pubmed">31671321</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>